BRAF V600突变阳性的晚期黑色素瘤治疗的临床研究进展  

Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma

作　　者：江健韵 应红梅[1,2] JIANG Jianyun;YING Hongmei(Department of Radiation Oncology,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China;Shanghai Key Laboratory of Radiation Oncology,Shanghai 200032,China)

机构地区：[1]复旦大学附属肿瘤医院放射治疗中心,复旦大学上海医学院肿瘤学系,上海200032 [2]上海市放射肿瘤学重点实验室,上海200032

出　　处：《中国癌症杂志》2022年第5期445-450,共6页China Oncology

摘　　要：多数黑色素瘤具有BRAF V600E/K突变,因此V600成为黑色素瘤精准治疗的重要靶点,并通常可被BRAF抑制剂和MEK抑制剂联合阻断。免疫检查点抑制剂的出现也极大地改善了BRAF V600突变阳性的晚期黑色素瘤患者的治疗结局,探究这部分患者的最佳一线治疗及序贯治疗顺序的临床试验正在开展。本文就精准医疗时代BRAF V600突变阳性的晚期黑色素瘤患者治疗的最新研究进展进行综述。Most melanomas have BRAF V600E/K mutations,making V600 an important target for precision treatment of melanoma,and it can often be blocked by a combination of BRAF inhibitors and MEK inhibitors.The emergence of immune checkpoint inhibitors has also greatly improved the treatment outcome of patients with BRAF V600 mutation-positive advanced melanoma.Clinical trials are also underway to determine the best first-line treatment and the sequence of combination therapies for these patients.This paper reviewed the latest progress in the treatment of BRAF V600 mutation-positive advanced melanoma in the era of precision medicine.

关 键 词：BRAF V600突变 晚期黑色素瘤 免疫检查点抑制剂 BRAF抑制剂 MEK抑制剂 

分 类 号：R739.5[医药卫生—肿瘤]